retinol has been researched along with fenretinide in 78 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (16.67) | 18.7374 |
| 1990's | 29 (37.18) | 18.2507 |
| 2000's | 22 (28.21) | 29.6817 |
| 2010's | 12 (15.38) | 24.3611 |
| 2020's | 2 (2.56) | 2.80 |
| Authors | Studies |
|---|---|
| Abraham, DJ; Balestreri, L; Cozzini, P; Kellogg, GE; Marabotti, A; Mozzarelli, A | 1 |
| Heikura, JM; Pohjala, LL; Riihimäki-Lampén, LH; Vahermo, M; Vainio, MJ; Valkonen, KH; Virtanen, VT; Vuorela, PM; Yli-Kauhaluoma, JT | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campos-Sandoval, JA; Eyre, GS; Findlay, JB; Hirst, SC; Jones, G; Kinsella, GK; Pal, A; Redondo, C | 1 |
| Green, MH; Lawless, DC; Moon, RC; Smith, JE | 1 |
| ElAttar, TM; Lin, HS | 1 |
| Campa, T; Costa, A; Crippa, A; Danesini, GM; De Palo, G; Delle Grottaglie, M; Di Mauro, MG; Formelli, F; Marubini, E; Rotmensz, N | 1 |
| Dimitrov, NV; Gilliland, D; Malone, W; Meyer, CJ; Minn, FL; Perloff, M; Phillipich, MJ; Ruppenthal, MM | 1 |
| Alberts, DS; Dalton, WS; Lim, H; Meyskens, FL; Peng, YM; Xu, MJ | 1 |
| Buranelli, F; Campa, T; Carsana, R; Costa, A; Dossena, G; Formelli, F; Magni, A; Pizzichetta, M | 1 |
| Creek, KE; De Luca, LM; Silverman-Jones, C; Sinha, R | 1 |
| Barua, AB; Furr, HC; Gallup, JM; Olson, JA | 1 |
| Crouch, RK; Goletz, P | 1 |
| Bunk, MJ; Kinahan, JJ; Sarkar, NH | 1 |
| Ball, MD; Furr, HC; Olson, JA | 1 |
| Newman, D; Oldham, JW; Paulson, JD; Preston, RF | 1 |
| Hultin, TA; Mehta, RG; Moon, RC | 1 |
| Hicks, RM | 1 |
| Moon, RC; Radcliffe, JD | 1 |
| DeHoog, JV; Moon, RC; Welsch, CW | 1 |
| Bertram, JS | 1 |
| Adams, WR; Green, MH; Smith, JE | 1 |
| Bruno, S; Decensi, A; Parodi, S; Polizzi, A; Torrisi, R | 1 |
| Berni, R; Folli, C; Malpeli, G; Marcello, M; Sartori, G; Zanotti, G | 1 |
| Boccardo, F; Costa, A; Decensi, A; Fontana, V; Formelli, F; Parodi, S; Rondanina, G; Torrisi, R | 1 |
| Costa, A; Decensi, A; Formelli, F; Torrisi, R | 1 |
| Lewis, KC; Phang, JM; Zech, LA | 2 |
| Chiesa, F; Costa, A; De Palo, G; Decensi, A; Formelli, F; Veronesi, U | 1 |
| Allen, LE; Green, JB; Green, MH | 1 |
| Brezzo, V; Costa, A; Decensi, A; Formelli, F; Gesi, R; Orengo, MA; Polizzi, A; Rolando, M; Rondanina, G; Torrisi, R | 1 |
| Dew, SE; Ong, DE; Wardlaw, SA | 1 |
| Ritter, SJ; Schaffer, EM; Smith, JE | 1 |
| Campa, T; Clerici, M; Costa, A; De Palo, G; Di Mauro, MG; Formelli, F; Magni, A; Mascotti, G; Moglia, D; Veronesi, U | 1 |
| Berni, R; Folli, C; Malpeli, G | 1 |
| Ritter, SJ; Smith, JE | 1 |
| Matsuura, T; Ross, AC; Zhao, Z | 1 |
| Accetturi, M; Baliva, G; Bono, A; De Palo, G; Formelli, F; Moglia, D; Nava, M | 1 |
| Gad, MZ; Harrison, EH; Matsuura, T; Ross, AC | 1 |
| Costa, A; Decensi, A; Fioretto, M; Fontana, V; Orengo, MA; Rondanina, G; Torrisi, R | 1 |
| Blomhoff, R; Moskaug, JO; Reppe, S; Smeland, S | 1 |
| Ayres, LM; Caruso, RC; Conley, BA; Iwata, F; Kaiser-Kupfer, MI; Podgor, MJ; Zujewski, J | 1 |
| Eto, I; Grubbs, CJ; Juliana, MM; Kelloff, GJ; Lubet, RA; Rodríguez-Burford, C; Steele, VE | 1 |
| Piantadosi, S | 1 |
| Boni, C; Camerini, T; Campa, T; Costa, A; D'Aiuto, G; De Palo, G; Decensi, A; Del Turco, MR; Del Vecchio, M; Di Mauro, MG; Formelli, F; Magni, A; Malone, WF; Mariani, L; Marubini, E; Miceli, R; Muraca, MG; Perloff, M; Pinto, C; Sporn, MB; Veronesi, U | 1 |
| Hochadel, JF; Lewis, KC | 1 |
| Meyskens, FL | 1 |
| Formelli, F | 2 |
| Arena, G; Baglietto, L; Decensi, A; Gonzaga, AG; Pasquetti, W; Robertson, C; Torrisi, R; Tosetti, F | 1 |
| Dillioglugil, O; Eichele, G; Frolov, A; Kadmon, D; Shalev, M; Thaller, C; Thompson, TC; Williams, RH | 1 |
| Abou-Issa, H; Alshafie, G; Chapman, JS; Clagett-Dame, M; Curley, RW; Mershon, SM; Weiss, KL | 1 |
| Brewer, M; Follen, M; Vlastos, AT; Wang, J; Yang, Li; Zou, C | 1 |
| Appierto, V; Camerini, T; Cavadini, E; Costa, A; De Palo, G; Di Mauro, MG; Formelli, F; Veronesi, U; Villani, MG | 1 |
| Bellani, FF; Boni, L; Cavadini, E; De Bernardi, B; Decensi, A; Formelli, F; Garaventa, A; Lo Piccolo, MS; Luksch, R; Montaldo, PG; Pizzitola, MR; Ponzoni, M | 1 |
| Chapman, JS; Clagett-Dame, M; Curley, RW; Highland, MA; Weiss, KL | 1 |
| Bok, D; Bui, TV; Han, Y; Lichter, J; Mata, NL; Nusinowitz, S; Radu, RA; Travis, GH; Widder, K | 1 |
| Bonanni, B; Cazzaniga, M; Decensi, A; Formelli, F; Franchi, D; Guerrieri-Gonzaga, A; Gulisano, M; Intra, M; Johansson, H; Johnson, K; Latronico, A; Mora, S; Pelosi, G; Robertson, C; Serrano, D | 1 |
| Ames, MM; Krailo, MD; Reaman, GH; Reid, JM; Reynolds, CP; Reynolds, PC; Villablanca, JG | 1 |
| Argusti, A; Baglietto, L; Cantù, MG; Cavadini, E; Colombo, N; Decensi, A; Formelli, F; Gasco, M; Guerrieri-Gonzaga, A; Montironi, R; Parma, G; Santinelli, A; Viale, G | 1 |
| Anding, AL; Barnett, DW; Chapman, JS; Clagett-Dame, M; Curley, RW | 1 |
| Higashiyama, K; Maitani, Y; Ohba, T; Takahashi, N; Watanabe, Y; Yamauchi, T | 1 |
| Jain, A; Marmor, MF; Moshfeghi, D | 1 |
| Conn, M; Coward, P; Menjares, A; Reagan, JD; Tang, J; Xiong, F | 1 |
| Berrino, F; Camerini, T; Cavadini, E; De Palo, G; Di Mauro, MG; Formelli, F; Meneghini, E; Micheli, A; Veronesi, U | 1 |
| Dunn, RL; Gadgeel, SM; Hodges, CM; Kalemkerian, GP; Kraut, MJ; Parchment, RE; Schneider, BJ; Worden, FP; Wozniak, AJ; Zwiebel, J | 1 |
| Bonanni, B; Cassano, E; Cazzaniga, M; Decensi, A; Formelli, F; Galimberti, V; Guerrieri-Gonzaga, A; Gulisano, M; Johansson, H; Johnson, KA; Lien, EA; Mora, S; Moroni, SM; Pelosi, G; Robertson, C; Serrano, D | 1 |
| Appierto, V; Cavadini, E; Formelli, F; Garaventa, A; Luksch, R; Persiani, S | 1 |
| Fleckenstein, M; Holz, FG; Mössner, A; Schmitz-Valckenberg, S; Wiedemann, P | 1 |
| Abzianidze, VV; Anding, AL; Clagett-Dame, M; Collins, MD; Curley, RW; Nieves, NJ | 1 |
| Acin-Perez, R; Fischman, D; Gong, J; Hammerling, U; Hoyos, B; Leitges, M; Manfredi, G; Shabrova, E; Vinogradov, V; Zhao, F | 1 |
| Burdan, F; Podlodowska, J; Podlodowski, W; Starosławska, E; Szumiło, J | 1 |
| Bui, TV; Han, Y; Lichter, JB; Mata, NL; Singerman, LJ; Vogel, R | 1 |
| Bonanni, B; Cazzaniga, M; Decensi, A; Formelli, F; Gandini, S; Guerrieri-Gonzaga, A; Gulisano, M; Johansson, H; Macis, D; Puccio, A; Sandri, MT; Serrano, D | 1 |
| Mcilroy, GD; Mody, N | 1 |
| Bulun, SE; Coon, JS; Dyson, M; Kim, JJ; Malpani, S; Mittal, N; Ono, M; Pavone, ME; Schink, JC | 1 |
| Amengual, J; Black, M; Miller, AP | 1 |
| Bissonnette, C; Din, C; Lin, YX; Liu, Y; Mallery, SR; Nieto, K; Pei, P; Schwendeman, SP; Shea, FF; Spinney, R; Wang, D | 1 |
5 review(s) available for retinol and fenretinide
| Article | Year |
|---|---|
The scientific basis for regarding vitamin A and its analogues as anti-carcinogenic agents.
Topics: Animals; Antineoplastic Agents; beta Carotene; Butylhydroxybutylnitrosamine; Carcinoma in Situ; Carcinoma, Papillary; Carotenoids; Cell Differentiation; Dose-Response Relationship, Drug; Epithelium; Fenretinide; Humans; Isotretinoin; Neoplasms; Neoplasms, Experimental; Tretinoin; Urinary Bladder Neoplasms; Vitamin A | 1983 |
Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide.
Topics: Anticarcinogenic Agents; Breast Neoplasms; Carcinoma, Basal Cell; Female; Fenretinide; Humans; Leukoplakia; Metabolic Clearance Rate; Mouth Neoplasms; Neoplasms; Vitamin A | 1994 |
[Therapy approaches for geographic atrophy].
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Carrier Proteins; cis-trans-Isomerases; Clinical Trials as Topic; Complement Inactivating Agents; Eye Proteins; Fenretinide; Geographic Atrophy; Humans; Neuroprotective Agents; Oxidative Stress; Receptor, Serotonin, 5-HT1A; Serotonin Receptor Agonists; Vision Tests; Vitamin A | 2010 |
[Chemoprevention of oral cancer--clinical and experimental studies].
Topics: Animals; Antineoplastic Agents; beta Carotene; Carcinoma, Squamous Cell; Chemoprevention; Drugs, Chinese Herbal; Fenretinide; Humans; Isotretinoin; Mouth Neoplasms; Neoplasm Recurrence, Local; Phytotherapy; Precancerous Conditions; Vitamin A | 2012 |
The mechanisms of Fenretinide-mediated anti-cancer activity and prevention of obesity and type-2 diabetes.
Topics: Animals; Antineoplastic Agents; Autophagy; Clinical Trials as Topic; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Type 2; Electron Transport; Fenretinide; Humans; Lipid Metabolism; Obesity; Reactive Oxygen Species; Retinoic Acid 4-Hydroxylase; Retinol-Binding Proteins, Plasma; Signal Transduction; Vitamin A | 2014 |
19 trial(s) available for retinol and fenretinide
| Article | Year |
|---|---|
Long-term tolerability of fenretinide (4-HPR) in breast cancer patients.
Topics: Affective Symptoms; Bone Density; Breast Neoplasms; Drug Eruptions; Drug Evaluation; Electroretinography; Female; Fenretinide; Follow-Up Studies; Humans; Tretinoin; Vision, Ocular; Vitamin A | 1991 |
Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Drug Evaluation; Female; Fenretinide; Follow-Up Studies; Humans; Tretinoin; Vitamin A | 1989 |
Pilot study of high dose fenretinide and vitamin A supplementation in bladder cancer.
Topics: Adult; Aged; Dark Adaptation; Female; Fenretinide; Humans; Male; Middle Aged; Pilot Projects; Urinary Bladder Neoplasms; Vitamin A | 1994 |
Breast cancer chemoprevention: studies with 4-HPR alone and in combination with tamoxifen using circulating growth factors as potential surrogate endpoints.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Drug Therapy, Combination; Drug Tolerance; Female; Fenretinide; Humans; Insulin-Like Growth Factor I; Middle Aged; Pilot Projects; Research Design; Tamoxifen; Transforming Growth Factor beta; Treatment Outcome; Vitamin A | 1993 |
Effect of the synthetic retinoid fenretinide on dark adaptation and the ocular surface.
Topics: Breast Neoplasms; Conjunctiva; Dark Adaptation; Eye; Female; Fenretinide; Humans; Vitamin A | 1994 |
Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations.
Topics: Adult; Aged; Analysis of Variance; Breast Neoplasms; Female; Fenretinide; Humans; Male; Middle Aged; Tretinoin; Vitamin A | 1993 |
Long-term effects of fenretinide on retinal function.
Topics: Age Factors; Antineoplastic Agents; Breast Neoplasms; Cohort Studies; Drug Administration Schedule; Electroretinography; Female; Fenretinide; Humans; Middle Aged; Photoreceptor Cells; Retina; Vitamin A | 1997 |
Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.
Topics: Adult; Aged; Anticarcinogenic Agents; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Female; Fenretinide; Humans; Incidence; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Proportional Hazards Models; Research Design; Risk; Risk Factors; Treatment Outcome; Vitamin A | 1999 |
Ocular effects of fenretinide, a vitamin A analog, in a chemoprevention trial of bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Carcinoma, Transitional Cell; Chemoprevention; Dark Adaptation; Female; Fenretinide; Follow-Up Studies; Humans; Lacrimal Apparatus; Logistic Models; Male; Middle Aged; Night Blindness; Odds Ratio; Patient Compliance; Urinary Bladder Neoplasms; Vision, Ocular; Vitamin A | 2000 |
Fenretinide therapy in prostate cancer: effects on tissue and serum retinoid concentration.
Topics: Aged; Animals; Antineoplastic Agents; Double-Blind Method; Fenretinide; Humans; Male; Mice; Mice, Inbred C57BL; Middle Aged; Placebos; Prostatectomy; Prostatic Neoplasms; Tretinoin; Vitamin A | 2000 |
Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome.
Topics: Adult; Age Factors; Aged; Anticarcinogenic Agents; Breast Neoplasms; Female; Fenretinide; Humans; Italy; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Time Factors; Vitamin A | 2003 |
Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Female; Fenretinide; Humans; Male; Neuroblastoma; Vitamin A | 2003 |
Preliminary results on safety and activity of a randomized, double-blind, 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Endometrium; Female; Fenretinide; Humans; Insulin-Like Growth Factor I; Middle Aged; Premenopause; Tamoxifen; Vitamin A | 2006 |
Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709).
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Drug Administration Schedule; Female; Fenretinide; Humans; Male; Neoplasm Recurrence, Local; Neoplasms; Neuroblastoma; Treatment Outcome; Vitamin A | 2006 |
A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Ascitic Fluid; Biomarkers, Tumor; CA-125 Antigen; Carcinoid Tumor; Case-Control Studies; Cell Proliferation; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Feasibility Studies; Female; Fenretinide; Fibrosarcoma; Humans; Ki-67 Antigen; Linear Models; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovariectomy; Treatment Outcome; Vitamin A | 2006 |
Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer.
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Fenretinide; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma; Survival Analysis; Time Factors; Treatment Outcome; Vitamin A | 2009 |
Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.
Topics: Adult; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Double-Blind Method; Drug Administration Schedule; Drug Synergism; Female; Fenretinide; Humans; Incidence; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Mammography; Middle Aged; Multivariate Analysis; Odds Ratio; Premenopause; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Vitamin A | 2009 |
Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Contrast Sensitivity; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fenretinide; Geographic Atrophy; Humans; Male; Middle Aged; Retinol-Binding Proteins, Plasma; Surveys and Questionnaires; Treatment Outcome; Visual Acuity; Vitamin A | 2013 |
Circulating hormones and breast cancer risk in premenopausal women: a randomized trial of low-dose tamoxifen and fenretinide.
Topics: Adult; Breast Density; Breast Neoplasms; Female; Fenretinide; Follow-Up Studies; Gonadal Steroid Hormones; Hormones; Humans; Incidence; Mammary Glands, Human; Middle Aged; Premenopause; Risk; Risk Factors; Sex Hormone-Binding Globulin; Tamoxifen; Vitamin A | 2013 |
54 other study(ies) available for retinol and fenretinide
| Article | Year |
|---|---|
HINT predictive analysis of binding between retinol binding protein and hydrophobic ligands.
Topics: Algorithms; Antineoplastic Agents; Diterpenes; Fenretinide; Humans; Ligands; Models, Molecular; Protein Binding; Retinol-Binding Proteins; Solubility; Tretinoin; Vitamin A | 2000 |
The binding of synthetic retinoids to lipocalin beta-lactoglobulins.
Topics: Animals; Binding Sites; Biological Availability; Cattle; Crystallography, X-Ray; Drug Design; Hydrogen-Ion Concentration; Lactoglobulins; Lipocalins; Models, Molecular; Molecular Structure; Reindeer; Retinoids; Structure-Activity Relationship | 2010 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Fenretinide derivatives act as disrupters of interactions of serum retinol binding protein (sRBP) with transthyretin and the sRBP receptor.
Topics: Fenretinide; Fluorescence; Fluorescence Resonance Energy Transfer; HEK293 Cells; Humans; Models, Molecular; Prealbumin; Protein Binding; Receptors, Cell Surface; Retinol-Binding Proteins; Serum; Stereoisomerism; Structure-Activity Relationship; Surface Plasmon Resonance | 2011 |
Secretion of vitamin A and retinol-binding protein into plasma is depressed in rats by N-(4-hydroxyphenyl)retinamide (fenretinide).
Topics: Animals; Fenretinide; Kidney; Kinetics; Liver; Lymph; Male; Rats; Rats, Inbred Strains; Retinol-Binding Proteins; Retinol-Binding Proteins, Plasma; Transferrin; Tretinoin; Triglycerides; Vitamin A | 1992 |
Effect of retinoids and carotenoids on prostaglandin formation by oral squamous carcinoma cells.
Topics: beta Carotene; Canthaxanthin; Carcinoma, Squamous Cell; Carotenoids; Chromatography, Thin Layer; Fenretinide; Humans; Indomethacin; Prostaglandins; Retinoids; Tongue Neoplasms; Tretinoin; Tumor Cells, Cultured; Vitamin A | 1991 |
Alteration of retinol-binding-protein concentrations by the synthetic retinoid fenretinide in healthy human subjects.
Topics: Adult; Drug Administration Schedule; Female; Fenretinide; Humans; Male; Retinol-Binding Proteins; Retinol-Binding Proteins, Plasma; Tretinoin; Vitamin A | 1990 |
Pharmacokinetics of N-4-hydroxyphenyl-retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients.
Topics: Administration, Oral; Breast Neoplasms; Chromatography, High Pressure Liquid; Drug Evaluation; Fenretinide; Humans; Melanoma; Mycosis Fungoides; Retinol-Binding Proteins; Retinol-Binding Proteins, Plasma; Tretinoin; Vitamin A | 1989 |
Retinoic acid treatment of fibroblasts causes a rapid decrease in [3H]inositol uptake.
Topics: Animals; Biological Transport; Carbohydrate Metabolism; Cell Division; Cell Line; Cell Line, Transformed; Diterpenes; Dose-Response Relationship, Drug; Ethylmaleimide; Fenretinide; Fibroblasts; Inositol; Inositol Phosphates; Kinetics; Phosphatidylinositols; Retinyl Esters; Tretinoin; Vitamin A | 1989 |
Effects of retinoid beta-glucuronides and N-retinoyl amines on the differentiation of HL-60 cells in vitro.
Topics: Cell Differentiation; Cell Division; Cell Line; Fenretinide; Humans; Leukemia, Myeloid, Acute; Nitroblue Tetrazolium; Oxidation-Reduction; Tretinoin; Vitamin A | 1987 |
Fenretinide does not block visual pigment formation in the rat.
Topics: Animals; Cattle; Eye Proteins; Fenretinide; Photoreceptor Cells; Rats; Rats, Inbred Strains; Retinal Pigments; Retinaldehyde; Rhodopsin; Rod Opsins; Tretinoin; Vitamin A | 1988 |
Biotransformation and protein binding of N-(4-hydroxyphenyl)retinamide in murine mammary epithelial cells.
Topics: Animals; Biotransformation; Carrier Proteins; Cells, Cultured; Female; Fenretinide; Mammary Neoplasms, Experimental; Mice; Protein Binding; Receptors, Retinoic Acid; Retinol-Binding Proteins; Tretinoin; Vitamin A | 1985 |
Enhancement of acyl coenzyme A:retinol acyltransferase in rat liver and mammary tumor tissue by retinyl acetate and its competitive inhibition by N-(4-hydroxyphenyl) retinamide.
Topics: Acyltransferases; Animals; Cell Line; Diterpenes; Female; Fenretinide; Kinetics; Liver; Mammary Neoplasms, Experimental; Microsomes, Liver; Rats; Rats, Inbred F344; Retinol O-Fatty-Acyltransferase; Retinyl Esters; Tretinoin; Vitamin A | 1985 |
Lack of genotoxicity of the cancer chemopreventive agent N-(4-hydroxyphenyl)retinamide.
Topics: Animals; Antineoplastic Agents; Bone Marrow Cells; Chromosome Aberrations; Cricetinae; Cytogenetics; Diterpenes; Fenretinide; Leukemia L5178; Male; Mesocricetus; Mice; Mitosis; Mutagenicity Tests; Rats; Retinoids; Retinyl Esters; Salmonella typhimurium; Tretinoin; Vitamin A | 1985 |
Simple high-performance liquid chromatographic method for the separation of retinoids including N-(4-hydroxyphenyl)-all-trans-retinamide.
Topics: Animals; Chromatography, High Pressure Liquid; Diterpenes; Female; Fenretinide; Liver; Mice; Rats; Rats, Inbred Strains; Retinoids; Retinyl Esters; Tretinoin; Vitamin A | 1985 |
Effect of N-(4-hydroxyphenyl) retinamide on food intake, growth, and mammary gland development in rats.
Topics: Adipose Tissue; Aging; Animals; Body Weight; Diet; Eating; Female; Fenretinide; Liver; Mammary Glands, Animal; Rats; Rats, Inbred Strains; Tretinoin; Vitamin A | 1983 |
Lack of an effect of dietary retinoids in chemical carcinogenesis of the mouse mammary gland: inverse relationship between mammary tumor cell anaplasia and retinoid efficacy.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Anaplasia; Animals; Diet; Diterpenes; Female; Fenretinide; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Inbred Strains; Retinoids; Retinyl Esters; Species Specificity; Tretinoin; Vitamin A | 1984 |
Structure-activity relationships among various retinoids and their ability to inhibit neoplastic transformation and to increase cell adhesion in the C3H/10T1/2 CL8 cell line.
Topics: Amides; Animals; Cell Adhesion; Cell Line; Cell Transformation, Neoplastic; Diterpenes; Fenretinide; Isotretinoin; Methylcholanthrene; Mice; Neoplasms, Experimental; Retinoids; Retinyl Esters; Structure-Activity Relationship; Tretinoin; Vitamin A | 1980 |
Effects of N-(4-hydroxyphenyl)retinamide on vitamin A metabolism in rats.
Topics: Animals; Fenretinide; Kidney; Liver; Male; Models, Biological; Rats; Rats, Sprague-Dawley; Retinol-Binding Proteins; Retinol-Binding Proteins, Plasma; Vitamin A | 1995 |
Crystallographic studies on complexes between retinoids and plasma retinol-binding protein.
Topics: Animals; Cattle; Crystallography, X-Ray; Diterpenes; Fenretinide; Protein Conformation; Retinoids; Retinol-Binding Proteins; Retinol-Binding Proteins, Plasma; Tretinoin; Vitamin A | 1994 |
Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid fenretinide in breast cancer patients.
Topics: Adipose Tissue; Adult; Age Factors; Aged; Body Mass Index; Breast Neoplasms; Cohort Studies; Dark Adaptation; Female; Fenretinide; Humans; Middle Aged; Population Surveillance; Postmenopause; Premenopause; Time Factors; Tretinoin; Vision, Ocular; Vitamin A | 1994 |
Effects of N-(4-hydroxyphenyl)retinamide supplementation on vitamin A metabolism.
Topics: Animals; Fenretinide; Kidney; Liver; Male; Rats; Rats, Sprague-Dawley; Retinol-Binding Proteins; Retinol-Binding Proteins, Plasma; Vitamin A | 1994 |
Correspondence re: S.E. Dew et al., Effects of pharmacological retinoids on several vitamin A-metabolizing enzymes. Cancer Res., 53: 2965-2969, 1993.
Topics: Acyltransferases; Alcohol Oxidoreductases; Animals; Anticarcinogenic Agents; Fenretinide; Intestinal Absorption; Intestines; Male; Rats; Rats, Sprague-Dawley; Retinoids; Retinol-Binding Proteins; Vitamin A | 1994 |
Effects of pharmacological retinoids on several vitamin A-metabolizing enzymes.
Topics: Acyltransferases; Alcohol Oxidoreductases; Animals; Cytochrome P450 Family 2; Fenretinide; Intestines; Isotretinoin; Liver; Microsomes, Liver; Rats; Retinoids; Retinol-Binding Proteins; Retinol-Binding Proteins, Plasma; Tretinoin; Vitamin A | 1993 |
N-(4-hydroxyphenyl)retinamide (fenretinide) induces retinol-binding protein secretion from liver and accumulation in the kidneys in rats.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Fenretinide; Kidney; Liver; Male; Prealbumin; Radioimmunoassay; Rats; Rats, Sprague-Dawley; Retinol-Binding Proteins; Retinol-Binding Proteins, Plasma; Serum Albumin; Time Factors; Transferrin; Vitamin A; Vitamin A Deficiency | 1993 |
Retinoid binding to retinol-binding protein and the interference with the interaction with transthyretin.
Topics: Animals; Antineoplastic Agents; Apoproteins; Chickens; Dansyl Compounds; Fenretinide; Fluorescence Polarization; Humans; Molecular Structure; Prealbumin; Protein Binding; Retinoids; Retinol-Binding Proteins; Retinol-Binding Proteins, Plasma; Thyroxine; Tretinoin; Vitamin A | 1996 |
Retinol-binding protein secretion from the liver of N-(4-hydroxyphenyl) retinamide-treated rats.
Topics: Animals; Antineoplastic Agents; Biological Transport; Cell Compartmentation; Colchicine; Fenretinide; Liver; Male; Prealbumin; Rats; Rats, Sprague-Dawley; Retinol-Binding Proteins; Retinol-Binding Proteins, Plasma; Vitamin A; Vitamin A Deficiency | 1996 |
N-(4-hydroxyphenyl)-retinamide increases lecithin:retinol acyltransferase activity in rat liver.
Topics: Acyltransferases; Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Fenretinide; Intestine, Small; Liver; Male; Rats; Rats, Inbred Lew; Time Factors; Vitamin A; Vitamin A Deficiency | 1996 |
Effects of chronic administration of N-(4-hydroxyphenyl)retinamide (4-HPR) in rats on vitamin A metabolism in the eye.
Topics: Animals; Antineoplastic Agents; Drug Administration Schedule; Eye; Fenretinide; Glycoproteins; Male; Models, Biological; Rats; Rats, Sprague-Dawley; Seminal Plasma Proteins; Vitamin A; Zn-Alpha-2-Glycoprotein | 1996 |
Effects of topical treatment with fenretinide (4-HPR) and plasma vitamin A levels in patients with actinic keratoses.
Topics: Administration, Topical; Adult; Anticarcinogenic Agents; Facial Dermatoses; Female; Fenretinide; Humans; Keratosis; Male; Middle Aged; Precancerous Conditions; Remission Induction; Vitamin A | 1996 |
Lecithin:retinol acyltransferase and retinyl ester hydrolase activities are differentially regulated by retinoids and have distinct distributions between hepatocyte and nonparenchymal cell fractions of rat liver.
Topics: Acyltransferases; Animals; Carboxylic Ester Hydrolases; Female; Fenretinide; Liver; Male; Rats; Rats, Inbred Lew; Tretinoin; Vitamin A; Vitamin A Deficiency | 1997 |
Retinol-induced secretion of human retinol-binding protein in yeast.
Topics: Adenosine Triphosphatases; Fenretinide; Fungal Proteins; Humans; Ligands; Mutation; Prealbumin; Protein Binding; Recombinant Fusion Proteins; Retinoids; Retinol-Binding Proteins; Retinol-Binding Proteins, Plasma; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Vesicular Transport Proteins; Vitamin A | 1998 |
Effects of fenretinide (4-HPR) on dark adaptation.
Topics: Adult; Antineoplastic Agents; Dark Adaptation; Female; Fenretinide; Humans; Male; Middle Aged; Photoreceptor Cells; Sensory Thresholds; Tretinoin; Vitamin A | 1998 |
Effect of reduced body weight gain on the evaluation of chemopreventive agents in the methylnitrosourea-induced mammary cancer model.
Topics: Animals; Anticarcinogenic Agents; Diterpenes; Energy Intake; Female; Fenretinide; Food Deprivation; Mammary Neoplasms, Experimental; Methylnitrosourea; Rats; Rats, Sprague-Dawley; Retinyl Esters; Vitamin A; Weight Gain | 1999 |
Vitamin A analogue for breast cancer prevention: a grade of F or incomplete?
Topics: Anticarcinogenic Agents; Breast Neoplasms; Female; Fenretinide; Humans; Neoplasms, Second Primary; Randomized Controlled Trials as Topic; Treatment Failure; Vitamin A | 1999 |
Retinoid metabolism in the prostate: effects of administration of the synthetic retinoid N-(4-hydroxyphenyl)retinamide.
Topics: Animals; Cell Division; Cell Survival; Cells, Cultured; Fenretinide; Humans; Kinetics; Male; Models, Biological; Prostate; Rats; Rats, Sprague-Dawley; Retinoids; Tissue Distribution; Vitamin A | 1999 |
Re: Vitamin A analogue for breast cancer prevention: a grade of F or incomplete?
Topics: Anticarcinogenic Agents; Breast Neoplasms; Clinical Trials as Topic; Confounding Factors, Epidemiologic; Female; Fenretinide; Humans; Research Design; Vitamin A | 2000 |
Quality control for HPLC assay and surrogate end point biomarkers from the fenretinide (4-HPR) breast cancer prevention trial.
Topics: Anticarcinogenic Agents; Biomarkers, Tumor; Breast Neoplasms; Case-Control Studies; Chromatography, High Pressure Liquid; Clinical Trials as Topic; Evaluation Studies as Topic; Female; Fenretinide; Humans; Insulin-Like Growth Factor I; Plasminogen Activators; Predictive Value of Tests; Quality Control; Reproducibility of Results; Tumor Suppressor Protein p53; Vitamin A | 2000 |
An unhydrolyzable analogue of N-(4-hydroxyphenyl)retinamide. synthesis and preliminary biological studies.
Topics: Animals; Antineoplastic Agents; Biotransformation; Female; Fenretinide; Hydrolysis; Mammary Neoplasms, Experimental; Rats; Vitamin A | 2001 |
Effect of 4-hydroxyphenylretinamide on human cervical epithelial and cancer cell lines.
Topics: Cell Division; Cell Line, Transformed; Cervix Uteri; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Epithelial Cells; Female; Fenretinide; Humans; Kinetics; Papillomaviridae; Tumor Cells, Cultured; Uterine Cervical Neoplasms; Vitamin A | 2003 |
Hydrolysis of 4-HPR to atRA occurs in vivo but is not required for retinamide-induced apoptosis.
Topics: Administration, Oral; Animals; Apoptosis; Body Weight; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Fenretinide; Humans; Hydrolysis; Male; Rats; Rats, Sprague-Dawley; Tretinoin; Vitamin A; Vitamin A Deficiency | 2003 |
Re: Lanvers C et al. Pharmacology of all-trans-retinoic acid in children with acute promyelocytic leukemia. Med Pediatr Oncol 2003;40:293-301.
Topics: Child; Fenretinide; Humans; Leukemia, Promyelocytic, Acute; Neurotoxicity Syndromes; Tretinoin; Vitamin A | 2004 |
Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases.
Topics: Animals; ATP-Binding Cassette Transporters; Chromatography, Gel; Chromatography, High Pressure Liquid; Dark Adaptation; Dose-Response Relationship, Drug; Electroretinography; Fenretinide; Lipofuscin; Mice; Mice, Inbred BALB C; Mice, Knockout; Microscopy, Fluorescence; Photic Stimulation; Pigment Epithelium of Eye; Prealbumin; Pyridinium Compounds; Retina; Retinal Degeneration; Retinoids; Retinol-Binding Proteins; Spectrometry, Fluorescence; Vitamin A | 2005 |
The unhydrolyzable fenretinide analogue 4-hydroxybenzylretinone induces the proapoptotic genes GADD153 (CHOP) and Bcl-2-binding component 3 (PUMA) and apoptosis that is caspase- dependent and independent of the retinoic acid receptor.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Caspases; Cell Line, Tumor; Cell Proliferation; Fenretinide; HL-60 Cells; Humans; Hydrolysis; Leukemia; Proto-Oncogene Proteins; Receptors, Retinoic Acid; Retinoids; RNA, Messenger; Transcription Factor CHOP; Vitamin A | 2007 |
p-Dodecylaminophenol derived from the synthetic retinoid, fenretinide: antitumor efficacy in vitro and in vivo against human prostate cancer and mechanism of action.
Topics: Aminophenols; Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Disease Models, Animal; Fenretinide; Humans; Male; Mice; Mice, Inbred BALB C; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Vitamin A | 2008 |
Total rod ERG suppression with high dose compassionate Fenretinide usage.
Topics: Adolescent; Antineoplastic Agents; Child; Dark Adaptation; Electroretinography; Female; Fenretinide; Humans; Male; Neuroblastoma; Retinal Diseases; Retinal Rod Photoreceptor Cells; Vitamin A | 2008 |
Application of an allosteric model to describe the interactions among retinol binding protein 4, transthyretin, and small molecule retinol binding protein 4 ligands.
Topics: Binding Sites; Diterpenes; Fenretinide; Fluorescence Resonance Energy Transfer; Humans; Kinetics; Ligands; Models, Biological; Prealbumin; Retinol-Binding Proteins, Plasma; Retinyl Esters; Structure-Activity Relationship; Vitamin A | 2009 |
Plasma retinol and prognosis of postmenopausal breast cancer patients.
Topics: Aged; Anticarcinogenic Agents; Breast Neoplasms; Chi-Square Distribution; Clinical Trials as Topic; Female; Fenretinide; Follow-Up Studies; Humans; Middle Aged; Postmenopause; Prognosis; Prospective Studies; Statistics, Nonparametric; Survival Rate; Vitamin A | 2009 |
Relationship among pharmacokinetics and pharmacodynamics of fenretinide and plasma retinol reduction in neuroblastoma patients.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Child; Chromatography, High Pressure Liquid; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Female; Fenretinide; Humans; Male; Neuroblastoma; Night Blindness; Vitamin A | 2010 |
4-Hydroxybenzyl modification of the highly teratogenic retinoid, 4-[(1E)-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-1-propen-1-yl]benzoic acid (TTNPB), yields a compound that induces apoptosis in breast cancer cells and shows reduced terato
Topics: Administration, Oral; Amides; Animals; Antineoplastic Agents; Apoptosis; Benzoates; Binding, Competitive; Breast Neoplasms; Cell Division; Cell Line, Tumor; Endoplasmic Reticulum; Female; Fenretinide; Humans; Phenol; Pregnancy; Rats; Rats, Sprague-Dawley; Receptors, Retinoic Acid; Retinoids; Teratogens; Transcription Factor CHOP; Vitamin A | 2011 |
Two protein kinase C isoforms, δ and ε, regulate energy homeostasis in mitochondria by transmitting opposing signals to the pyruvate dehydrogenase complex.
Topics: Animals; Cell Line; Citric Acid Cycle; Energy Metabolism; Enzyme Activation; Fenretinide; Homeostasis; Mice; Mitochondria, Liver; Oxidative Phosphorylation; Phosphorylation; Protein Kinase C-delta; Protein Kinase C-epsilon; Pyruvate Dehydrogenase Complex; Signal Transduction; Vitamin A; Zinc Fingers | 2012 |
Fenretinide: a novel treatment for endometrial cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progression; Endometrial Neoplasms; Female; Fenretinide; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Megestrol Acetate; Membrane Proteins; Mice, Nude; Vitamin A; Xenograft Model Antitumor Assays | 2014 |
Fenretinide inhibits vitamin A formation from β-carotene and regulates carotenoid levels in mice.
Topics: Animals; beta Carotene; Body Weight; Dioxygenases; Fenretinide; Intestinal Absorption; Intestines; Liver; Mice, Inbred C57BL; Models, Biological; Retinol-Binding Proteins, Plasma; Vitamin A; Vitamin A Deficiency; Vitamin E | 2022 |
Fenretinide combines perturbation of signaling kinases, cell-extracellular matrix interactions and matrix metalloproteinase activation to inhibit invasion in oral squamous cell carcinoma cells.
Topics: Actins; Adenosine Triphosphate; Carcinoma, Squamous Cell; Caspase 3; Cell Line, Tumor; Extracellular Matrix; Fenretinide; Head and Neck Neoplasms; Humans; Matrix Metalloproteinases; Mouth Neoplasms; Neoplasm Invasiveness; Squamous Cell Carcinoma of Head and Neck; Vitamin A | 2022 |